NASDAQ:VTVT - vTv Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $2.78 +0.06 (+2.21 %) (As of 01/23/2019 10:42 AM ET)Previous Close$2.72Today's Range$2.70 - $2.7852-Week Range$0.65 - $8.40Volume553 shsAverage Volume5.56 million shsMarket Capitalization$113.29 millionP/E Ratio-1.61Dividend YieldN/ABeta-4.18 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company's drug candidates comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials for the treatment of Alzheimer's disease. Its drug candidates also include TTP399, an orally administered, liver-selective glucokinase activator that has completed Phase 2b clinical trials for the treatment of type 2 diabetes, as well as initiated Phase 1b/2 clinical trials for the treatment of type 1 diabetes; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor, which has completed Phase II clinical trials for the treatment of type 2 diabetes. vTv Therapeutics Inc. has a license and research agreement with Calithera Biosciences, Inc. to develop and commercialize its hexokinase II inhibitors for therapeutic, prophylactic, preventative, or diagnostic use. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of vTv Therapeutics Holdings LLC. Receive VTVT News and Ratings via Email Sign-up to receive the latest news and ratings for VTVT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VTVT Previous Symbol CUSIPN/A Webwww.vtvtherapeutics.com Phone336-841-0300Debt Debt-to-Equity RatioN/A Current Ratio0.23 Quick Ratio0.23Price-To-Earnings Trailing P/E Ratio-1.61 Forward P/E Ratio-3.81 P/E GrowthN/A Sales & Book Value Annual Sales$290,000.00 Price / Sales390.64 Cash FlowN/A Price / Cash FlowN/A Book Value($4.60) per share Price / Book-0.60Profitability EPS (Most Recent Fiscal Year)($1.67) Net Income$-16,140,000.00 Net Margins-136.66% Return on EquityN/A Return on Assets-67.27%Miscellaneous Employees56 Outstanding Shares40,750,000Market Cap$113.29 million OptionableNot Optionable vTv Therapeutics (NASDAQ:VTVT) Frequently Asked Questions What is vTv Therapeutics' stock symbol? vTv Therapeutics trades on the NASDAQ under the ticker symbol "VTVT." How were vTv Therapeutics' earnings last quarter? vTv Therapeutics Inc (NASDAQ:VTVT) announced its quarterly earnings results on Thursday, November, 8th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.06. The biotechnology company had revenue of $3.38 million for the quarter, compared to analyst estimates of $2.06 million. View vTv Therapeutics' Earnings History. When is vTv Therapeutics' next earnings date? vTv Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for vTv Therapeutics. What price target have analysts set for VTVT? 5 brokerages have issued twelve-month price objectives for vTv Therapeutics' stock. Their forecasts range from $4.00 to $28.00. On average, they expect vTv Therapeutics' share price to reach $15.75 in the next twelve months. This suggests a possible upside of 479.0% from the stock's current price. View Analyst Price Targets for vTv Therapeutics. What is the consensus analysts' recommendation for vTv Therapeutics? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for vTv Therapeutics in the last year. There are currently 5 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for vTv Therapeutics. Has vTv Therapeutics been receiving favorable news coverage? Media stories about VTVT stock have trended very positive recently, InfoTrie reports. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. vTv Therapeutics earned a news impact score of 3.7 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future. Who are some of vTv Therapeutics' key competitors? Some companies that are related to vTv Therapeutics include Corbus Pharmaceuticals (CRBP), Clementia Pharmaceuticals (CMTA), Beyondspring (BYSI), Progenics Pharmaceuticals (PGNX), MediciNova (MNOV), ArQule (ARQL), American Brivision (Holding) (ABVC), Synthorx (THOR), Five Prime Therapeutics (FPRX), Kezar Life Sciences (KZR), Cytokinetics (CYTK), TG Therapeutics (TGTX), Sinovac Biotech (SVA), Akebia Therapeutics (AKBA) and Xeris Pharmaceuticals (XERS). Who are vTv Therapeutics' key executives? vTv Therapeutics' management team includes the folowing people: Mr. Jeffrey B. Kindler, Exec. Chairman (Age 63)Mr. Stephen L. Holcombe, Pres & CEO (Age 62)Mr. Rudy C. Howard CPA, B.A., CPA, Exec. VP & CFO (Age 61)Dr. Carmen Valcarce Ph.D., Chief Scientific Officer & Exec. VPMs. Robin E. Abrams, Exec. VP & Gen. Counsel (Age 55) When did vTv Therapeutics IPO? (VTVT) raised $125 million in an initial public offering (IPO) on Thursday, July 30th 2015. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Piper Jaffray and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers. How do I buy shares of vTv Therapeutics? Shares of VTVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is vTv Therapeutics' stock price today? One share of VTVT stock can currently be purchased for approximately $2.72. How big of a company is vTv Therapeutics? vTv Therapeutics has a market capitalization of $110.84 million and generates $290,000.00 in revenue each year. The biotechnology company earns $-16,140,000.00 in net income (profit) each year or ($1.67) on an earnings per share basis. vTv Therapeutics employs 56 workers across the globe. What is vTv Therapeutics' official website? The official website for vTv Therapeutics is http://www.vtvtherapeutics.com. How can I contact vTv Therapeutics? vTv Therapeutics' mailing address is 4170 MENDENHALL OAKS PKWY, HIGH POINT NC, 27265. The biotechnology company can be reached via phone at 336-841-0300 or via email at [email protected] MarketBeat Community Rating for vTv Therapeutics (NASDAQ VTVT)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 218 (Vote Outperform)Underperform Votes: 207 (Vote Underperform)Total Votes: 425MarketBeat's community ratings are surveys of what our community members think about vTv Therapeutics and other stocks. Vote "Outperform" if you believe VTVT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VTVT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/23/2019 by MarketBeat.com StaffFeatured Article: How does a reverse stock split work?